Mrsa | Press Release


Research and Markets ( ) has announced the addition of GlobalData ‘s new report ” Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics – Pipeline Assessment and Market Forecasts to 2017 ” to their offering.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics – Pipeline Assessment and Market Forecasts to 2017 report is an essential source of information and analysis on the global MRSA market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The MRSA Market Is In High Growth Trajectory Mode That Is Expected To Mature By 2017.

The global Methicillin-resistant Staphylococcus aureus (MRSA) market was valued at $900m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.8% for the next seven years to reach $1,249m by 2017. The growth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial antibiotic treatment and steady increases in elderly and immuno-suppressed populations. At present, the market has six approved therapies, out of which Vancomycin and Synercid (quinupristin+dalfopristin) are generic and the other four are branded drugs.


Currently, the market is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin). As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline), Vibativ (televancin) and Synercid are capable of curing the disease, there are still unmet needs which can be tapped with those emerging agents which have better safety profiles.

Strong Market Consists of Six Therapies That Increased the MRSA Therapeutics Market

Pfizer, Theravance Inc., and Cubist Pharmaceuticals remain the leading competitors in the global MRSA therapeutics market. The competitive landscape is strong, with six approved therapies. The market remains highly consolidated. These players captured the market in the past few years and are expected to be the market leaders for next three to four years with products like Zyvox, Cubicin and Vibativ until new players emerge, like Takeda/Forest with


Click here to view rest of article from original site

Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic

26 new from $7.99
Mrsa - Spider Bites: The Flesh-eating Bacterial Epidemic That Threatens Mrsa – Spider Bites: The Flesh-eating Bacterial Epidemic That Threatens
merica  by Hernan R. Chang
12 new from $7.84



Facebook Twitter Email